View Financial HealthThis company has been acquiredThe company may no longer be operating, as it has been acquired. Find out why through their latest events.See Latest EventsLa Jolla Pharmaceutical 配当と自社株買い配当金 基準チェック /06La Jolla Pharmaceutical配当金を支払った記録がありません。主要情報n/a配当利回り7.1%バイバック利回り総株主利回り7.1%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesMajor Estimate Revision • Aug 22Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$52.8m to US$46.9m. EPS estimate unchanged from US$0.04 per share at last update. Biotechs industry in the US expected to see average net income decline 57% next year. Consensus price target of US$6.23 unchanged from last update. Share price was steady at US$6.22 over the past week.Reported Earnings • Aug 16Second quarter 2022 earnings released: EPS: US$0.097 (vs US$0.14 in 2Q 2021)Second quarter 2022 results: EPS: US$0.097 (down from US$0.14 in 2Q 2021). Revenue: US$10.5m (down 34% from 2Q 2021). Net income: US$2.46m (down 34% from 2Q 2021). Profit margin: 23% (in line with 2Q 2021). Over the next year, revenue is forecast to grow 20%, compared to a 41% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 106% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Jul 11Investor sentiment improved over the past weekAfter last week's 97% share price gain to US$6.14, the stock trades at a forward P/E ratio of 71x. Average forward P/E is 10x in the Biotechs industry in the US. Total loss to shareholders of 34% over the past three years.Seeking Alpha • Jul 11Innoviva to acquire La Jolla Pharma for $149M including debtInnoviva, Inc. (INVA), a diversified holding company, has agreed to acquire the commercial-stage biotech La Jolla Pharmaceutical Company (NASDAQ:LJPC) for $6.23 per share in cash, implying an enterprise value of ~$149M, the companies announced on Monday. Per the terms of the merger agreement, Innoviva (INVA) intends to pay $5.95 per share for La Jolla (LJPC) and $0.28 per share for additional cash proceeds from the divestiture of a non-core asset. The initial purchase price of $5.95 indicates a premium of 70% to the 30-day volume-weighted average price (VWAP). Innoviva (INVA), through one of its subsidiaries, will start a tender offer in this regard on or before July 25, 2022. The deal is expected to close within 30 business days. In 2017, the FDA approved La Jolla’s (LJPC) lead product to increase blood pressure in adults with septic or other distributive shock. A year later, the agency greenlighted its second product XERAVA as a treatment for adults with complicated intra-abdominal infections. The company reported $43.5M of net product sales in 2021 with ~30% YoY growth.Valuation Update With 7 Day Price Move • Jun 15Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to US$3.20, the stock trades at a forward P/E ratio of 37x. Average forward P/E is 9x in the Biotechs industry in the US. Total loss to shareholders of 64% over the past three years.Major Estimate Revision • May 23Consensus EPS estimates fall by 60%The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from US$55.6m to US$52.8m. EPS estimate also fell from US$0.10 per share to US$0.04 per share. Net income forecast to shrink 46% next year vs 52% decline forecast for Biotechs industry in the US. Consensus price target of US$4.00 unchanged from last update. Share price fell 8.2% to US$3.82 over the past week.Reported Earnings • May 17First quarter 2022 earnings: EPS and revenues miss analyst expectationsFirst quarter 2022 results: EPS: US$0 (down from US$0.53 in 1Q 2021). Revenue: US$10.4m (down 70% from 1Q 2021). Net income: US$2.0k (down 100% from 1Q 2021). Profit margin: 0% (down from 42% in 1Q 2021). Revenue missed analyst estimates by 20%. Earnings per share (EPS) were also behind analyst estimates. Over the next year, revenue is forecast to grow 12%, compared to a 36% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 98% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.Price Target Changed • Apr 27Price target decreased to US$4.00Down from US$4.50, the current price target is provided by 1 analyst. New target price is approximately in line with last closing price of US$3.91. Stock is down 7.8% over the past year. The company is forecast to post earnings per share of US$0.10 for next year compared to US$0.72 last year.Major Estimate Revision • Mar 16Consensus forecasts updatedThe consensus outlook for 2022 has been updated. Biotechs industry in the US expected to see average net income decline 42% next year. Consensus price target of US$4.00 unchanged from last update. Share price fell 2.1% to US$4.25 over the past week.Reported Earnings • Mar 11Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2021 results: EPS: US$0.72 (up from US$1.44 loss in FY 2020). Revenue: US$75.7m (up 127% from FY 2020). Net income: US$19.7m (up US$59.1m from FY 2020). Profit margin: 26% (up from net loss in FY 2020). The move to profitability was primarily driven by higher revenue. Products in clinical trials Phase III: 1 Revenue missed analyst estimates by 2.3%. Earnings per share (EPS) exceeded analyst estimates by 9.4%. Over the next year, revenue is expected to shrink by 26% compared to a 61% growth forecast for the pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 90% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.Recent Insider Transactions • Dec 08Independent Director recently bought US$92k worth of stockOn the 6th of December, David Ramsay bought around 25k shares on-market at roughly US$3.75 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$194k more in shares than they have sold in the last 12 months.Valuation Update With 7 Day Price Move • Nov 23Investor sentiment improved over the past weekAfter last week's 21% share price gain to US$4.85, the stock trades at a forward P/E ratio of 36x. Average forward P/E is 14x in the Biotechs industry in the US. Total loss to shareholders of 70% over the past three years.分析記事 • Nov 11We Think La Jolla Pharmaceutical's (NASDAQ:LJPC) Robust Earnings Are ConservativeThe subdued stock price reaction suggests that La Jolla Pharmaceutical Company's ( NASDAQ:LJPC ) strong earnings didn't...Reported Earnings • Nov 06Third quarter 2021 earnings released: US$0.082 loss per share (vs US$0.43 loss in 3Q 2020)The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: US$13.3m (up 47% from 3Q 2020). Net loss: US$2.26m (loss narrowed 81% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 79% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Aug 26Investor sentiment improved over the past weekAfter last week's 17% share price gain to US$4.30, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 13x in the Biotechs industry in the US. Total loss to shareholders of 82% over the past three years.Valuation Update With 7 Day Price Move • Aug 12Investor sentiment improved over the past weekAfter last week's 18% share price gain to US$4.18, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 13x in the Biotechs industry in the US. Total loss to shareholders of 80% over the past three years.Reported Earnings • Aug 09Second quarter 2021 earnings released: EPS US$0.14 (vs US$0.57 loss in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: US$16.1m (up 177% from 2Q 2020). Net income: US$3.73m (up US$19.3m from 2Q 2020). Profit margin: 23% (up from net loss in 2Q 2020). Over the last 3 years on average, earnings per share has increased by 65% per year but the company’s share price has fallen by 44% per year, which means it is significantly lagging earnings.Price Target Changed • Aug 06Price target decreased to US$4.50Down from US$9.33, the current price target is provided by 1 analyst. New target price is 13% above last closing price of US$3.99. Stock is up 11% over the past year.Seeking Alpha • Jul 02Our Take On La Jolla Pharmaceutical CompanyLa Jolla Pharmaceutical Company (LJPC) strengthened its balance sheet with upfront money from the EU commercial rights to its two septic shock related products. Although Giapreza sales have been uninspiring since its 2018 launch, the company is nearing cash flow positive, owing to the lack of a meaningful R&D effort since a 2019 restructuring. With a market cap less than two times forecasted 2022 sales and insider buying, La Jolla merited a deeper dive. A full investment analysis follows in the paragraphs below.Recent Insider Transactions • May 27Independent Director recently bought US$70k worth of stockOn the 24th of May, David Ramsay bought around 20k shares on-market at roughly US$3.49 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$261k more in shares than they have sold in the last 12 months.Reported Earnings • May 08First quarter 2021 earnings released: EPS US$0.53 (vs US$0.32 loss in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: US$34.1m (up 350% from 1Q 2020). Net income: US$14.4m (up US$23.0m from 1Q 2020). Profit margin: 42% (up from net loss in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has fallen by 49% per year, which means it is significantly lagging earnings.分析記事 • Mar 11La Jolla Pharmaceutical's (NASDAQ:LJPC) Shareholders Are Down 82% On Their SharesWhile it may not be enough for some shareholders, we think it is good to see the La Jolla Pharmaceutical Company...Reported Earnings • Mar 10Full year 2020 earnings released: US$1.44 loss per share (vs US$4.30 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: US$33.4m (up 45% from FY 2019). Net loss: US$39.4m (loss narrowed 66% from FY 2019). Products in clinical trials Phase III: 1 Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 47% per year, which means it is significantly lagging earnings.Analyst Estimate Surprise Post Earnings • Mar 10Revenue beats expectations, earnings disappointRevenue exceeded analyst estimates by 2.6%. Earnings per share (EPS) missed analyst estimates by 13%. Over the next year, revenue is forecast to grow 107%, compared to a 1,438% growth forecast for the Biotechs industry in the US.分析記事 • Feb 11Market Sentiment Around Loss-Making La Jolla Pharmaceutical Company (NASDAQ:LJPC)We feel now is a pretty good time to analyse La Jolla Pharmaceutical Company's ( NASDAQ:LJPC ) business as it appears...Is New 90 Day High Low • Feb 05New 90-day high: US$7.33The company is up 105% from its price of US$3.57 on 06 November 2020. The American market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 22% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$45.64 per share.Price Target Changed • Jan 27Price target raised to US$11.94Up from US$10.67, the current price target is an average from 3 analysts. The new target price is 85% above the current share price of US$6.46. As of last close, the stock is down 7.4% over the past year.分析記事 • Jan 16Industry Analysts Just Upgraded Their La Jolla Pharmaceutical Company (NASDAQ:LJPC) Revenue Forecasts By 18%Celebrations may be in order for La Jolla Pharmaceutical Company ( NASDAQ:LJPC ) shareholders, with the analysts...Is New 90 Day High Low • Jan 13New 90-day high: US$5.04The company is up 22% from its price of US$4.14 on 14 October 2020. The American market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 16% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$37.00 per share.分析記事 • Jan 05Should You Take Comfort From Insider Transactions At La Jolla Pharmaceutical Company (NASDAQ:LJPC)?It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...分析記事 • Dec 09Could The La Jolla Pharmaceutical Company (NASDAQ:LJPC) Ownership Structure Tell Us Something Useful?The big shareholder groups in La Jolla Pharmaceutical Company ( NASDAQ:LJPC ) have power over the company. Generally...Analyst Estimate Surprise Post Earnings • Nov 11Revenue beats expectations, earnings disappointRevenue exceeded analyst estimates by 40%. Earnings per share (EPS) missed analyst estimates by 20%. Over the next year, revenue is forecast to grow 78%, compared to a 372% growth forecast for the Biotechs industry in the US.Reported Earnings • Nov 11Third quarter 2020 earnings released: US$0.43 loss per shareThe company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: US$9.07m (up 59% from 3Q 2019). Net loss: US$11.8m (loss narrowed 60% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 51% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Oct 30New 90-day low: US$3.40The company is down 15% from its price of US$3.98 on 31 July 2020. The American market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$47.33 per share.決済の安定と成長配当データの取得安定した配当: LJPCの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: LJPCの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場La Jolla Pharmaceutical 配当利回り対市場LJPC 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (LJPC)n/a市場下位25% (US)1.4%市場トップ25% (US)4.2%業界平均 (Biotechs)2.4%アナリスト予想 (LJPC) (最長3年)n/a注目すべき配当: LJPCは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: LJPCは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: LJPCの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: LJPCが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2022/08/22 06:29終値2022/08/19 00:00収益2022/06/30年間収益2021/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋La Jolla Pharmaceutical Company 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。11 アナリスト機関Keay NakaeChardan Capital Markets, LLCReni BenjaminH.C. Wainwright & Co.Eun Kyung YangJefferies LLC8 その他のアナリストを表示
Major Estimate Revision • Aug 22Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$52.8m to US$46.9m. EPS estimate unchanged from US$0.04 per share at last update. Biotechs industry in the US expected to see average net income decline 57% next year. Consensus price target of US$6.23 unchanged from last update. Share price was steady at US$6.22 over the past week.
Reported Earnings • Aug 16Second quarter 2022 earnings released: EPS: US$0.097 (vs US$0.14 in 2Q 2021)Second quarter 2022 results: EPS: US$0.097 (down from US$0.14 in 2Q 2021). Revenue: US$10.5m (down 34% from 2Q 2021). Net income: US$2.46m (down 34% from 2Q 2021). Profit margin: 23% (in line with 2Q 2021). Over the next year, revenue is forecast to grow 20%, compared to a 41% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 106% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Jul 11Investor sentiment improved over the past weekAfter last week's 97% share price gain to US$6.14, the stock trades at a forward P/E ratio of 71x. Average forward P/E is 10x in the Biotechs industry in the US. Total loss to shareholders of 34% over the past three years.
Seeking Alpha • Jul 11Innoviva to acquire La Jolla Pharma for $149M including debtInnoviva, Inc. (INVA), a diversified holding company, has agreed to acquire the commercial-stage biotech La Jolla Pharmaceutical Company (NASDAQ:LJPC) for $6.23 per share in cash, implying an enterprise value of ~$149M, the companies announced on Monday. Per the terms of the merger agreement, Innoviva (INVA) intends to pay $5.95 per share for La Jolla (LJPC) and $0.28 per share for additional cash proceeds from the divestiture of a non-core asset. The initial purchase price of $5.95 indicates a premium of 70% to the 30-day volume-weighted average price (VWAP). Innoviva (INVA), through one of its subsidiaries, will start a tender offer in this regard on or before July 25, 2022. The deal is expected to close within 30 business days. In 2017, the FDA approved La Jolla’s (LJPC) lead product to increase blood pressure in adults with septic or other distributive shock. A year later, the agency greenlighted its second product XERAVA as a treatment for adults with complicated intra-abdominal infections. The company reported $43.5M of net product sales in 2021 with ~30% YoY growth.
Valuation Update With 7 Day Price Move • Jun 15Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to US$3.20, the stock trades at a forward P/E ratio of 37x. Average forward P/E is 9x in the Biotechs industry in the US. Total loss to shareholders of 64% over the past three years.
Major Estimate Revision • May 23Consensus EPS estimates fall by 60%The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from US$55.6m to US$52.8m. EPS estimate also fell from US$0.10 per share to US$0.04 per share. Net income forecast to shrink 46% next year vs 52% decline forecast for Biotechs industry in the US. Consensus price target of US$4.00 unchanged from last update. Share price fell 8.2% to US$3.82 over the past week.
Reported Earnings • May 17First quarter 2022 earnings: EPS and revenues miss analyst expectationsFirst quarter 2022 results: EPS: US$0 (down from US$0.53 in 1Q 2021). Revenue: US$10.4m (down 70% from 1Q 2021). Net income: US$2.0k (down 100% from 1Q 2021). Profit margin: 0% (down from 42% in 1Q 2021). Revenue missed analyst estimates by 20%. Earnings per share (EPS) were also behind analyst estimates. Over the next year, revenue is forecast to grow 12%, compared to a 36% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 98% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
Price Target Changed • Apr 27Price target decreased to US$4.00Down from US$4.50, the current price target is provided by 1 analyst. New target price is approximately in line with last closing price of US$3.91. Stock is down 7.8% over the past year. The company is forecast to post earnings per share of US$0.10 for next year compared to US$0.72 last year.
Major Estimate Revision • Mar 16Consensus forecasts updatedThe consensus outlook for 2022 has been updated. Biotechs industry in the US expected to see average net income decline 42% next year. Consensus price target of US$4.00 unchanged from last update. Share price fell 2.1% to US$4.25 over the past week.
Reported Earnings • Mar 11Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2021 results: EPS: US$0.72 (up from US$1.44 loss in FY 2020). Revenue: US$75.7m (up 127% from FY 2020). Net income: US$19.7m (up US$59.1m from FY 2020). Profit margin: 26% (up from net loss in FY 2020). The move to profitability was primarily driven by higher revenue. Products in clinical trials Phase III: 1 Revenue missed analyst estimates by 2.3%. Earnings per share (EPS) exceeded analyst estimates by 9.4%. Over the next year, revenue is expected to shrink by 26% compared to a 61% growth forecast for the pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 90% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.
Recent Insider Transactions • Dec 08Independent Director recently bought US$92k worth of stockOn the 6th of December, David Ramsay bought around 25k shares on-market at roughly US$3.75 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$194k more in shares than they have sold in the last 12 months.
Valuation Update With 7 Day Price Move • Nov 23Investor sentiment improved over the past weekAfter last week's 21% share price gain to US$4.85, the stock trades at a forward P/E ratio of 36x. Average forward P/E is 14x in the Biotechs industry in the US. Total loss to shareholders of 70% over the past three years.
分析記事 • Nov 11We Think La Jolla Pharmaceutical's (NASDAQ:LJPC) Robust Earnings Are ConservativeThe subdued stock price reaction suggests that La Jolla Pharmaceutical Company's ( NASDAQ:LJPC ) strong earnings didn't...
Reported Earnings • Nov 06Third quarter 2021 earnings released: US$0.082 loss per share (vs US$0.43 loss in 3Q 2020)The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: US$13.3m (up 47% from 3Q 2020). Net loss: US$2.26m (loss narrowed 81% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 79% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Aug 26Investor sentiment improved over the past weekAfter last week's 17% share price gain to US$4.30, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 13x in the Biotechs industry in the US. Total loss to shareholders of 82% over the past three years.
Valuation Update With 7 Day Price Move • Aug 12Investor sentiment improved over the past weekAfter last week's 18% share price gain to US$4.18, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 13x in the Biotechs industry in the US. Total loss to shareholders of 80% over the past three years.
Reported Earnings • Aug 09Second quarter 2021 earnings released: EPS US$0.14 (vs US$0.57 loss in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: US$16.1m (up 177% from 2Q 2020). Net income: US$3.73m (up US$19.3m from 2Q 2020). Profit margin: 23% (up from net loss in 2Q 2020). Over the last 3 years on average, earnings per share has increased by 65% per year but the company’s share price has fallen by 44% per year, which means it is significantly lagging earnings.
Price Target Changed • Aug 06Price target decreased to US$4.50Down from US$9.33, the current price target is provided by 1 analyst. New target price is 13% above last closing price of US$3.99. Stock is up 11% over the past year.
Seeking Alpha • Jul 02Our Take On La Jolla Pharmaceutical CompanyLa Jolla Pharmaceutical Company (LJPC) strengthened its balance sheet with upfront money from the EU commercial rights to its two septic shock related products. Although Giapreza sales have been uninspiring since its 2018 launch, the company is nearing cash flow positive, owing to the lack of a meaningful R&D effort since a 2019 restructuring. With a market cap less than two times forecasted 2022 sales and insider buying, La Jolla merited a deeper dive. A full investment analysis follows in the paragraphs below.
Recent Insider Transactions • May 27Independent Director recently bought US$70k worth of stockOn the 24th of May, David Ramsay bought around 20k shares on-market at roughly US$3.49 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$261k more in shares than they have sold in the last 12 months.
Reported Earnings • May 08First quarter 2021 earnings released: EPS US$0.53 (vs US$0.32 loss in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: US$34.1m (up 350% from 1Q 2020). Net income: US$14.4m (up US$23.0m from 1Q 2020). Profit margin: 42% (up from net loss in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has fallen by 49% per year, which means it is significantly lagging earnings.
分析記事 • Mar 11La Jolla Pharmaceutical's (NASDAQ:LJPC) Shareholders Are Down 82% On Their SharesWhile it may not be enough for some shareholders, we think it is good to see the La Jolla Pharmaceutical Company...
Reported Earnings • Mar 10Full year 2020 earnings released: US$1.44 loss per share (vs US$4.30 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: US$33.4m (up 45% from FY 2019). Net loss: US$39.4m (loss narrowed 66% from FY 2019). Products in clinical trials Phase III: 1 Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 47% per year, which means it is significantly lagging earnings.
Analyst Estimate Surprise Post Earnings • Mar 10Revenue beats expectations, earnings disappointRevenue exceeded analyst estimates by 2.6%. Earnings per share (EPS) missed analyst estimates by 13%. Over the next year, revenue is forecast to grow 107%, compared to a 1,438% growth forecast for the Biotechs industry in the US.
分析記事 • Feb 11Market Sentiment Around Loss-Making La Jolla Pharmaceutical Company (NASDAQ:LJPC)We feel now is a pretty good time to analyse La Jolla Pharmaceutical Company's ( NASDAQ:LJPC ) business as it appears...
Is New 90 Day High Low • Feb 05New 90-day high: US$7.33The company is up 105% from its price of US$3.57 on 06 November 2020. The American market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 22% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$45.64 per share.
Price Target Changed • Jan 27Price target raised to US$11.94Up from US$10.67, the current price target is an average from 3 analysts. The new target price is 85% above the current share price of US$6.46. As of last close, the stock is down 7.4% over the past year.
分析記事 • Jan 16Industry Analysts Just Upgraded Their La Jolla Pharmaceutical Company (NASDAQ:LJPC) Revenue Forecasts By 18%Celebrations may be in order for La Jolla Pharmaceutical Company ( NASDAQ:LJPC ) shareholders, with the analysts...
Is New 90 Day High Low • Jan 13New 90-day high: US$5.04The company is up 22% from its price of US$4.14 on 14 October 2020. The American market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 16% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$37.00 per share.
分析記事 • Jan 05Should You Take Comfort From Insider Transactions At La Jolla Pharmaceutical Company (NASDAQ:LJPC)?It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...
分析記事 • Dec 09Could The La Jolla Pharmaceutical Company (NASDAQ:LJPC) Ownership Structure Tell Us Something Useful?The big shareholder groups in La Jolla Pharmaceutical Company ( NASDAQ:LJPC ) have power over the company. Generally...
Analyst Estimate Surprise Post Earnings • Nov 11Revenue beats expectations, earnings disappointRevenue exceeded analyst estimates by 40%. Earnings per share (EPS) missed analyst estimates by 20%. Over the next year, revenue is forecast to grow 78%, compared to a 372% growth forecast for the Biotechs industry in the US.
Reported Earnings • Nov 11Third quarter 2020 earnings released: US$0.43 loss per shareThe company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: US$9.07m (up 59% from 3Q 2019). Net loss: US$11.8m (loss narrowed 60% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 51% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Oct 30New 90-day low: US$3.40The company is down 15% from its price of US$3.98 on 31 July 2020. The American market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$47.33 per share.